RecruitingNCT07059923

Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment

400 participants

Start Date

Jul 1, 2025

Study Type

OBSERVATIONAL

Conditions

Lung Cancer (Diagnosis)

Summary

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using artificial intelligence (AI) and a technique called radiomics — which extracts detailed patterns from CT scan images — to predict how well lung cancer patients will respond to immunotherapy treatment and how long they will survive. The goal is to improve treatment decision-making using imaging data. **You may be eligible if...** - You were treated for lung cancer at Wuhan Union Hospital between July 2025 and July 2026 - You are 18 years of age or older - You had at least one CT scan before starting treatment - Your lung cancer diagnosis was confirmed by a tissue biopsy **You may NOT be eligible if...** - Your CT scan images are of poor quality - Your clinical data is incomplete or you were lost to follow-up - You have a second primary cancer (a separate unrelated cancer) - You are not a lung cancer patient treated at the specified hospital during the specified time period Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07059923

Related Trials

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

NCT075525842 locations

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT071689933 locations

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT0746584812 locations

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

NCT074399911 location

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT074106761 location